Matthias Vennemann

This inventor holds 11 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: 4Sc Ag, Bayer Intellectual Property Gmbh, Altana Pharma Ag. Active years: 2010-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Vennemann. Retrieved from https://idiyas.com/inventor/matthias-vennemann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 4)

% Patents Active = 36.4

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Constance, DE (2010 - 2015)
Berlin, DE (2015)

Company Filing History:

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

patents

Years Active: 2010-2015

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8969401 - Sulfonylpyrroles (2015-03-03),

2. 8957064 - Fused pyrimidines (2015-02-17),

3. 8614218 - Fused bicyclic pyrimidines (2013-12-24),

4. 8530493 - Indolopyridines as Eg5 kinesin modulators (2013-09-10),

5. 8440830 - Tetrahydro-fused pyridines as histone deacetylase inhibitors (2013-05-14),

6. 8399505 - Sulfonylpyrroles (2013-03-19),

7. 8067615 - Sulphonylpyrroles (2011-11-29),

8. 8044065 - Benzothienopyridines for use as inhibitors of Eg5 kinesin (2011-10-25),

9. 7842820 - Sulfonylpyrroles (2010-11-30),

10. 7776864 - Fused bicyclic pyrimidines (2010-08-17),

11. 7718665 - Benzothienopyridines for use as inhibitors of Eg5 kinesin (2010-05-18),

Title: The Innovative Mind of Matthias Vennemann

Introduction

Matthias Vennemann, based in Constance, Germany, is a prolific inventor with a remarkable portfolio of 11 patents. His work primarily focuses on novel compounds with significant implications in the field of medicinal chemistry, particularly regarding effective inhibitors.

Latest Patents

Among his latest innovations, Vennemann has developed patents related to "Sulfonylpyrroles," which are identified as novel effective HDAC inhibitors. These compounds are defined by a specific formula where R1, R2, R3, R4, R5, R6, and R7 have designated meanings as outlined in the patent's description. Another noteworthy patent includes "Fused Pyrimidines," providing potential breakthroughs in pharmaceutical applications.

Career Highlights

Vennemann has made significant contributions while working for prominent companies such as 4SC AG and Bayer Intellectual Property GmbH. His tenure at these organizations has allowed him to hone his skills and push the boundaries of research and development in the pharmaceutical sector.

Collaborations

Throughout his career, Matthias has collaborated with notable colleagues, including Thomas Beckers and Thomas Maier. These professional relationships have fostered a productive environment for innovation and the advancement of crucial scientific concepts.

Conclusion

Matthias Vennemann stands out as a key figure in the realm of invention and innovation. His extensive patent portfolio, coupled with his contributions to leading companies, demonstrates his commitment to advancing science and technology. As he continues to explore new horizons in medicinal chemistry, the impact of his work is sure to resonate within the industry for years to come.

Profile summary based on public USPTO records.